Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects

BACKGROUND AND OBJECTIVE: AZD5718, a 5-lipoxygenase-activating protein (FLAP) inhibitor, is in clinical development for treatment of coronary artery disease (CAD) and chronic kidney disease (CKD). This study evaluated AZD5718 pharmacokinetics, pharmacodynamics, and tolerability in healthy male Japan...

Descripción completa

Detalles Bibliográficos
Autores principales: Knöchel, Jane, Nelander, Karin, Heijer, Maria, Lindstedt, Eva-Lotte, Forsberg, Gun-Britt, Whatling, Carl, Shimada, Hitoshi, Han, David S., Gabrielsen, Anders, Garkaviy, Pavlo, Ericsson, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481180/
https://www.ncbi.nlm.nih.gov/pubmed/34546534
http://dx.doi.org/10.1007/s40261-021-01078-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481180/
https://www.ncbi.nlm.nih.gov/pubmed/34546534
http://dx.doi.org/10.1007/s40261-021-01078-7

Ejemplares similares